Close
Close
Treatment Database
a long-acting interleukin-11 analog comprised of 178 amino acids covalently modified wiht a 40-kDa branched maleimide-polyethylene glycol at the added cysteine residue following the carboxy-terminal amino acid
Trade Name not avaiable
Orphan Indication Acute radiation syndrome
USA Market Approval
USA Designation Date 17-04-2019
Sponsor Bolder BioTechnology, Inc.
2425 55th Street, Suite 210
Boulder, Colorado, 80301
More about Acute radiation syndrome
Free Newsletter
Related Videos
by Salima Mathews
8,409 views